Ipsen SA IPN.PA

A leading French pharmaceutical company, Ipsen provides medication and healthcare products in oncology, neuroscience, and diseases. Headquartered in Paris, France, Ipsen also owns three research facilities in Cambridge, Massachusetts, Paris and Oxford, in the United Kingdom. Like many other companies, Ipsen has become active in terms of acquisitions, purchasing biopharmaceutical company Clementia Pharmaceuticals for $1.3 billion in 2019.

Trading on the Euronext Paris, IPN.PA stock went public in a 2005 IPO. Ipsen was able to raise €324 million as a result, with shares valued at €22.20 each. IPN.PA is also part of the CAC Mid 60 Component and the SBF 120 Index, with the latter comprised of the 120 most traded stocks in Paris.

With the help of several leading research institutions and IGOs, Ipsen created the Ipsen Foundation in 1983. The goal was to monitor the progress of biomedical research. This prestigious list of partners includes Harvard University, the World Health Organization, and Massachusetts General Hospital. The foundation is located near Paris, in the suburb of Boulogne-Billancourt.

Trade IPN.PA by adding the stock to your eToro portfolio. Track value changes on the platform in real time.